Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bright Minds Biosciences Inc DRUG


Primary Symbol: C.DRUG

Healthcare Biotechnology
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant... see more

Recent & Breaking News (CSE:DRUG)

Bright Minds Biosciences to Present at the Benzinga Global Small Cap Conference

GlobeNewswire May 11, 2021

Bright Minds Biosciences (CSE:DRUG) expands scientific advisory team

Brieanna McCutcheon  April 27, 2021

Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team

GlobeNewswire April 27, 2021

New Research Finds Promise in Psychiatric Use Of Psilocybin; North American Companies Explore Full Potential

Press Releases April 26, 2021

Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

GlobeNewswire March 17, 2021

Canadian Securities Exchange Shatters Previous Monthly Trading Volume Record

Newsfile March 15, 2021

Bright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

GlobeNewswire March 15, 2021

Bright Minds Biosciences to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis

GlobeNewswire March 10, 2021

Bright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

GlobeNewswire March 3, 2021

The Need for Psychedelic Medicine is Now. Who Will Save Us?

Livemoney March 3, 2021

IIROC Trade Resumption - DRUG

Canada NewsWire February 23, 2021

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of Units

GlobeNewswire February 23, 2021

IIROC Trading Halt - DRUG

Canada NewsWire February 23, 2021

Bright Minds Biosciences Inc. Announces Marketed Public Offering

GlobeNewswire February 22, 2021

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future Growth

GlobeNewswire February 10, 2021

Bright Minds Biosciences (CSE:DRUG) strengthens scientific advisory team

Brieanna McCutcheon  February 10, 2021

Psychedelic Treatments Providing Hope for the Mental Health Pandemic

Livemoney February 9, 2021